Although MDA5+DM-ILD is now recognized as a distinct clinical entity, up to 30 % of patients may not meet the 2017 EULAR/ACR criteria for idiopathic inflammatory myopathies (IIM) [16]. This evidence concerns the gene IFIH1 and interstitial lung disease.